Lutetium Lu 177 Vipivotide Tetraxetan Boosts rPFS in Taxane-Naïve mCRPC After Prior AR Inhibitor
October 23rd 2023
Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor.